Physician profile
Thomas Cestare
NPI 1013303320
$1,744.75
in general payments reported to CMS, 2019-2025
7 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,144 · 2020: $187 · 2021: $135 · 2022: $279.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $939.04 | 2019-2020 | |
| Nevro Corp. | $265.69 | 2019 | |
| Abbott Laboratories | $178.07 | 2022 | |
| Medtronic, INC. | $135.39 | 2021 | |
| Avanos Medical | $112.64 | 2019-2020 | |
| Grt US Holding, INC. | $100.80 | 2022 | |
| Spr Therapeutics, INC | $13.12 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Cestare listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.